WHO ICTRP trial
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical…
ACTRN12605000577617 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12605000577617 |
|---|---|
| Public title | Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial |
| Scientific title | Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial |
| Primary sponsor | University of Melbourne |
| Secondary sponsors | Royal Adelaide Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Australia |
| Conditions | Schizophrenia; Schizophrenia;Mental Health - Schizophrenia |
| Interventions | 6-week trial of mirtazapine (30 mg/day) in addition to antipsychotic treatment as usual. |
| Registration date | Apr 10, 2005 |
| Target size | 40 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: